Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants
Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the preva...
Saved in:
Published in | EJHaem Vol. 5; no. 5; pp. 1021 - 1027 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.10.2024
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 2688-6146 2688-6146 |
DOI | 10.1002/jha2.1012 |
Cover
Abstract | Introduction
Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold.
Methods
A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells.
Results
All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%.
Conclusion
Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin. |
---|---|
AbstractList | Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. Methods A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells. Results All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Conclusion Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin. Abstract Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. Methods A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells. Results All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Conclusion Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin. Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds' accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3 cells. All the selected variants were not found in CD3 cells except one variant in the gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin. Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds’ accuracy we have explored the prevalence of germline variants below the 30% VAF threshold. Methods A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells. Results All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%. Conclusion Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin. Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds' accuracy we have explored the prevalence of germline variants below the 30% VAF threshold.IntroductionGermline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency (VAF) higher than 30% for point mutations in specific genes. To investigate the VAF thresholds' accuracy we have explored the prevalence of germline variants below the 30% VAF threshold.A total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells.MethodsA total of 40 variants with VAF lower than 30% in bone marrow samples of myeloid neoplasm patients were selected and studied in CD3+ cells.All the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%.ResultsAll the selected variants were not found in CD3+ cells except one variant in the SF3B1 gene. However, the whole series was found somatic. Selected variants were also evaluated with our previously studied series of 52 variants with VAF higher than 30%.Our study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin.ConclusionOur study suggests that variants with VAF below 30% are strong somatic candidates but the variants with VAF higher than 30% cannot be considered of germline origin. |
Author | Mestre, Julia Manzanares, Ana Xicoy, Blanca Chaparro, Lorea Sole, Francesc Zamora, Lurdes Calvete, Oriol |
AuthorAffiliation | 3 Department of Hematology ICO‐IJC‐Hospital Germans Trias i Pujol, UAB Badalona Catalonia Spain 2 Facultat de Biociències Universitat Autònoma de Barcelona Barcelona Spain 1 MDS Group Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona Badalona Spain |
AuthorAffiliation_xml | – name: 2 Facultat de Biociències Universitat Autònoma de Barcelona Barcelona Spain – name: 1 MDS Group Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona Badalona Spain – name: 3 Department of Hematology ICO‐IJC‐Hospital Germans Trias i Pujol, UAB Badalona Catalonia Spain |
Author_xml | – sequence: 1 givenname: Julia orcidid: 0000-0002-4809-3897 surname: Mestre fullname: Mestre, Julia organization: Universitat Autònoma de Barcelona – sequence: 2 givenname: Lorea orcidid: 0009-0008-6806-9342 surname: Chaparro fullname: Chaparro, Lorea organization: Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona – sequence: 3 givenname: Ana surname: Manzanares fullname: Manzanares, Ana organization: Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona – sequence: 4 givenname: Blanca orcidid: 0000-0002-0295-1307 surname: Xicoy fullname: Xicoy, Blanca organization: ICO‐IJC‐Hospital Germans Trias i Pujol, UAB – sequence: 5 givenname: Lurdes orcidid: 0000-0003-1713-7110 surname: Zamora fullname: Zamora, Lurdes organization: ICO‐IJC‐Hospital Germans Trias i Pujol, UAB – sequence: 6 givenname: Francesc orcidid: 0000-0002-3251-2161 surname: Sole fullname: Sole, Francesc email: fsole@carrerasresearch.org organization: Universitat Autònoma de Barcelona – sequence: 7 givenname: Oriol orcidid: 0000-0002-2623-2876 surname: Calvete fullname: Calvete, Oriol email: ocalvete@carrerasresearch.org organization: Josep Carreras Leukaemia Research Institute, ICO‐Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39415912$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1u1DAQgC1UREvpgRdAkbjAYWn8mzWXqlRAiypxqbhaXnuy8cqxg50U7QPw3ji7ZdUicbA88nz-NPbMS3QUYgCEXuP6A65rcr7pNCkRJs_QCRHL5UJgJo4excfoLOdNXViKuaD4BTqmkmEuMTlBvz_BNgZb9Vvw0dkqQBy8zn2u1pB67wJU68lZmKP8sfqhvbN6dDFUsa3GDspKkLvoba5MciMkpysXdqkMOpluBg-uIYF1eYjZ7Rz3uuBhzK_Q81b7DGcP-ym6-_L57up6cfv9683V5e3CMNGQBRBJZdtyboQ02nDCCOOU1owBA2pMebFmFngjCG81WCLACmBkxWzLMKOn6GavtVFv1JBcr9NWRe3U7iCmtdJpdMaDatpa2KUGDZwysWIaCyaZoITaVjaNLa6LvWuYVj1YA2FM2j-RPs0E16l1vFcYs4ZRKYvh3YMhxZ8T5FH1LhvwXpcmTFlRjBuBJeG8oG__QTdxSqF81UwJTpqaN4V687ikQy1_u12A93vApJhzgvaA4FrNw6TmYVLzMBX2fM_-ch62_wfVt-tLsrvxBywmzGs |
Cites_doi | 10.1038/s41375-022-01729-4 10.1007/s00428‐022‐03447‐9 10.18632/oncotarget.23882 10.1111/bjh.18675 10.3390/ijms17060838 10.1097/HS9.0000000000000321 10.1182/blood.2022015790 10.1182/bloodadvances.2019001127 10.1182/blood.2022015853 10.1111/bjh.18676 10.6004/jnccn.2022.0009 10.1038/s41576-019-0139-x |
ContentType | Journal Article |
Copyright | 2024 The Author(s). published by British Society for Haematology and John Wiley & Sons Ltd. 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024 The Author(s). published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION NPM 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1002/jha2.1012 |
DatabaseName | Wiley Online Library Open Access CrossRef PubMed ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student SciTech Premium Collection ProQuest Biological Science Collection Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) (Open Access) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | MESTRE et al |
EISSN | 2688-6146 |
EndPage | 1027 |
ExternalDocumentID | oai_doaj_org_article_7f06d8aeae5346b4a164946323df977d PMC11474399 39415912 10_1002_jha2_1012 JHA21012 |
Genre | shortCommunication Journal Article |
GrantInformation_xml | – fundername: Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) funderid: 2023 FI‐1 00200 – fundername: Instituto de Salud Carlos III funderid: PI 20/000531; PI23/00007 – fundername: Joan Oró predoctoral programfrom Secretariad' Universitat siRecercadel Departamentde Recercai Universitats delaGeneralitatde Catalunya – fundername: European Social Funding Plus (FSE+) – fundername: José Carreras Leukämie‐Stiftung 2020 funderid: DJCLS01R/2021; 2021SGR00560 – fundername: (GRC) Generalitat de Catalunya: CERCA Programme/Generalitat de Catalunya – fundername: Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) grantid: 2023 FI‐1 00200 – fundername: José Carreras Leukämie‐Stiftung 2020 grantid: DJCLS01R/2021; 2021SGR00560 |
GroupedDBID | 0R~ 1OC 24P 53G AAHHS ACCFJ ACCMX ACXQS ADKYN ADPDF ADZMN AEEZP AEQDE AFKRA AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BBNVY BENPR BHPHI CCPQU EBS GROUPED_DOAJ HCIFZ IAO IHR INH ITC M7P M~E OVD OVEED PGMZT PIMPY RPM TEORI WIN AAFWJ AAYXX AFPKN CITATION PHGZM PHGZT NPM 8FE 8FH AAMMB ABUWG AEFGJ AGXDD AIDQK AIDYY AZQEC DWQXO GNUQQ LK8 PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c4672-e2939ff55c69cac52424533044e4e3cc688a4de57625faed26ed6e42b4df4143 |
IEDL.DBID | 24P |
ISSN | 2688-6146 |
IngestDate | Wed Aug 27 01:27:37 EDT 2025 Thu Aug 21 18:31:24 EDT 2025 Fri Sep 05 09:46:05 EDT 2025 Wed Aug 13 10:35:25 EDT 2025 Wed Feb 19 02:01:37 EST 2025 Tue Jul 01 04:19:30 EDT 2025 Wed Jan 22 17:13:33 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | myelodysplastic syndromes (MDS) variant allele frequency (VAF) germline guidelines germline predisposition |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4672-e2939ff55c69cac52424533044e4e3cc688a4de57625faed26ed6e42b4df4143 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-3251-2161 0000-0002-4809-3897 0000-0003-1713-7110 0000-0002-2623-2876 0009-0008-6806-9342 0000-0002-0295-1307 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.1012 |
PMID | 39415912 |
PQID | 3116527057 |
PQPubID | 5066168 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_7f06d8aeae5346b4a164946323df977d pubmedcentral_primary_oai_pubmedcentral_nih_gov_11474399 proquest_miscellaneous_3117619255 proquest_journals_3116527057 pubmed_primary_39415912 crossref_primary_10_1002_jha2_1012 wiley_primary_10_1002_jha2_1012_JHA21012 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2024 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: October 2024 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | EJHaem |
PublicationTitleAlternate | EJHaem |
PublicationYear | 2024 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 2022; 36 2018; 9 2022; 140 2020; 4 2019; 20 2016; 17 2023; 482 2022 Feb; 20 2022 2019 Dec; 3 2023; 201 e_1_2_13_13_1 e_1_2_13_14_1 e_1_2_13_15_1 e_1_2_13_10_1 e_1_2_13_11_1 e_1_2_13_12_1 e_1_2_13_9_1 e_1_2_13_8_1 e_1_2_13_7_1 e_1_2_13_6_1 e_1_2_13_5_1 e_1_2_13_4_1 e_1_2_13_3_1 e_1_2_13_2_1 |
References_xml | – volume: 9 start-page: 9714 issue: 11 year: 2018 end-page: 9727 article-title: Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms publication-title: Oncotarget – volume: 3 issue: 6 year: 2019 Dec article-title: Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management, and follow‐up publication-title: . Hemasphere. – volume: 20 start-page: 106 issue: 2 year: 2022 Feb end-page: 117 article-title: NCCN Guidelines® Insights: myelodysplastic syndromes, Version 3.2022 publication-title: J Natl Compr Canc Netw – volume: 201 issue: 1 year: 2023 article-title: Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough? publication-title: Br J Haematol – year: 2022 – volume: 140 start-page: 2533 issue: 24 year: 2022 end-page: 2548 article-title: Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages publication-title: Blood – volume: 36 start-page: 2827 issue: 12 year: 2022 end-page: 2834 article-title: Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia publication-title: Leukemia – volume: 4 start-page: 1192 issue: 7 year: 2020 end-page: 1196 article-title: The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing publication-title: Blood Adv – volume: 17 start-page: 838 issue: 6 year: 2016 article-title: hereditary predispositions to myelodysplastic syndrome publication-title: Int J Mol Sci – volume: 140 start-page: 2228 issue: 21 year: 2022 end-page: 2247 article-title: Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia publication-title: Blood – volume: 20 start-page: 582 issue: 10 year: 2019 end-page: 598 article-title: Somatic genetic rescue in Mendelian haematopoietic diseases publication-title: Nat Rev Genet – volume: 482 start-page: 113 issue: 1 year: 2023 end-page: 130 article-title: The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia publication-title: Virchows Archiv [Internet] – volume: 201 start-page: 25 issue: 1 year: 2023 end-page: 34 article-title: Germline predisposition to haematological malignancies: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene‐CanVar and the NHS England Haematological Oncology Working Group publication-title: Br J Haematol – ident: e_1_2_13_10_1 doi: 10.1038/s41375-022-01729-4 – ident: e_1_2_13_4_1 doi: 10.1007/s00428‐022‐03447‐9 – ident: e_1_2_13_15_1 doi: 10.18632/oncotarget.23882 – ident: e_1_2_13_8_1 doi: 10.1111/bjh.18675 – ident: e_1_2_13_2_1 doi: 10.3390/ijms17060838 – ident: e_1_2_13_6_1 doi: 10.1097/HS9.0000000000000321 – ident: e_1_2_13_7_1 – ident: e_1_2_13_9_1 doi: 10.1182/blood.2022015790 – ident: e_1_2_13_12_1 doi: 10.1182/bloodadvances.2019001127 – ident: e_1_2_13_14_1 doi: 10.1182/blood.2022015853 – ident: e_1_2_13_11_1 doi: 10.1111/bjh.18676 – ident: e_1_2_13_3_1 – ident: e_1_2_13_5_1 doi: 10.6004/jnccn.2022.0009 – ident: e_1_2_13_13_1 doi: 10.1038/s41576-019-0139-x |
SSID | ssj0002315631 |
Score | 2.2734017 |
Snippet | Introduction
Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele... Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele frequency... Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a variant allele... Abstract Introduction Germline predisposition to myeloid neoplasms can be suspected in patients younger than 50 years or when harboring mutations with a... |
SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1021 |
SubjectTerms | CD3 antigen Clinical practice guidelines DNA methylation Gene frequency germline guidelines germline predisposition Lymphocytes myelodysplastic syndromes (MDS) Patients Point mutation Short Report Trends Tumors variant allele frequency (VAF) |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NTxsxEB1VHKpeqtLPbSkyqIdeVgR_7bo3iooiJDjRitvKa8_SoLJBhCDxA_jfnbE3UaK26oVDpCh2IsczY79Zv3kG-IQuhFhbU0Y78qVuUZVt5RxFvI3WOhNtquI_ObXj7_r43JyvXPXFnLAsD5wnbq_q6Fu1R49GadtqT_jeaaukih1hl8ir78iNVpKpyyTiQnmJ2l9ICY3k3iUXrrKY1doGlHT6_wYu_-RIrmLXtPkcvYDnA2oUB3m0m_AE-5fw9GQ4F38FD7kQRVzd46_pJIqeeeF-djUTF7TyMpIUF3MWtGKS-xfxg8B3vktJTDtBEJBelHbzSdRM0DLC-s1eTPrUlGOBOy5_6_qGq3kXfC9xR_k202lew9nRt7PDcTlcsFAGWh9libTXu64zJlgXfDBcKsJsU61RowrB1rXXESklkabzGKXFaFHLVsdOE9B6Axv9tMd3IBin0Xx30RvUVXB1rKhvbVXlsQ77bQG7i0lvrrOMRpMFk2XDlmGmmSzgK5tj2YGVr9MH5A_N4A_N__yhgK2FMZshHGeNYpEhWRE2LWBn2UyBxKcjnmwyT334kQ6lWAW8zbZfjkQ5wjmOR1ivecXaUNdb-snPJNZN-WbK-Qr4nBzo33-_OR4fSH7z_jHm4QM8k4S_Mu9wCzZub-b4kfDTbbudQuU3W9IapQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7SDZReQvp2kxa19NCLSaKXrUIpSUlYAllKSUtuRpbk7YbE3uxmC_0B_d-dkR_t0sfBYCxhJI9m_I008w3A62Cc87lWqdf7NpVlEGmZGYMar73WRnkds_jPJnr8WZ5eqIsNmPS5MBRW2dvEaKh942iPfE8QTwzPEF68n9-kVDWKTlf7Ehq2K63g30WKsTuwyamq8gg2j44nHz8Nuy6IZpQWBz3F0D7fu6SEViK5WvsxRf7-v4HOP2Mnf8e08ad0sg1bHZpkh63478NGqB_A3bPuvPwh_GgTVNj193DVzDyrKV7cLq-XbIoWmRAmm66I6IqC39-yLwjK2xpLrKkYQkO80B2nE6olQ_NCvM6WzerY1OoIdRzeNV9Qlm8fB8a-oR9OYTaP4Pzk-PzDOO0KL6QO7SZPA2IAU1VKOW2cdYpSSCgKVcogg3BO57mVPqCrwlVlg-c6eB0kL6WvJAKwxzCqmzo8BUb4Db935a0KMnMm9xn2zbXIbMjdQZnAq_6jF_OWXqNoiZR5QZKhCDSewBGJY-hAjNjxQbOYFp2CFVmFqyu3wQYlpC6lRT_QSC248BViXJ_Abi_MolPTZfFrUSXwcmhGBaNTE4syWcU-tNWDrlcCT1rZDyMRBvGPoRHma6tibajrLfXsayTxRj80-oIJvIkL6N_TL07Hh5xunv1_CjtwjyPiaiMNd2F0u1iF54iYbssXnRr8BI7tGN4 priority: 102 providerName: ProQuest |
Title | Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.1012 https://www.ncbi.nlm.nih.gov/pubmed/39415912 https://www.proquest.com/docview/3116527057 https://www.proquest.com/docview/3117619255 https://pubmed.ncbi.nlm.nih.gov/PMC11474399 https://doaj.org/article/7f06d8aeae5346b4a164946323df977d |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fSxwxEB6sQumL9HfX2iMtPvRlUbNJdqNPWpRDUES0-LZkk-z1St2TW0_wD-j_3Zlkd-vRFvpwsFzmjmwmk3wzmfkCsOW1ta5QMnVqx6Si8lla5VqjxSunlJZOhSr-0zM1vhIn1_J6Bfb7WpjIDzEE3MgywnpNBm6qdvs3aeh3qkQldqonsLZLuz7ROovzIcCCwEWqcB8hVzgbcBtSPbPQDt8efr20HwXa_r9hzT9TJh9D2bAXHT-H9Q5EsoOo9Rew4puX8PS0OyZ_BT9jXQq7efA_ZlPHGkoTN-1Nyya4ENOrs8mC-K0o532PfUUsHq9WYrOaISLED3rhdDDVMlxViM7ZsGkTmqJpkODwX7dzKu7t07_YPbrflF3zGi6Pjy6_jNPuvoXU4nLJU49bv65rKa3S1lhJlSOUfCqEFz6zFofRCOfRQ-GyNt5x5Z3yglfC1QI18AZWm1nj3wEj2IZjXzsjvcitLlyOsoXKcuMLu1sl8Kkf9PI2smqUkT-Zl6QZSjzjCRySOgYBIsIOX8zmk7KzqzKvcVIVxhsvM6EqYdD900JlPHM1QluXwGavzLKzzrbMiHOI5whVE_g4NKNd0WGJQZ0sggxFeNDjSuBt1P3Qk0wj7NHUw2JpVix1dbmlmX4L3N04U4MLmMDnMIH-_frlyfiA08PG_4u-h2ccQVdMNtyE1bv5wn9A0HRXjYJxjGDt8Ojs_GIUQg-jENv6BQvDF5g |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwEB2VVgJeEHcCBQwCiZeorWM7CVKFWmi1vewKoQX1LXJsZ1lEk2XTBfUD-Cz-jRnnAisub31YKVpbkeOZsc_YM2cAnrnUGJsoGVq1qUORuyjM4zRFi1dWqVRa5bP4hyM1eC8OT-TJCvzocmEorLJbE_1CbStDZ-QbEfHE8BjhxavZl5CqRtHtaldCQ7elFey2pxhrEzuO3Pk3dOHq7YM3KO_nnO_vjV8PwrbKQGhwkeChww0vLQopjUqNNpLyJSjkUggnXGSMShItrENczmWhneXKWeUEz4UtBKINfO0lWEPUEaFRre3ujd6-6w95EDxJFW11jEabfOMT5c8Sp9bSPujLBfwN4_4Zqvk7hPZ74P51uNaCV7bTaNsNWHHlTbg8bK_nb8H3Jh-GnZ67z9XUspLC03V9WrMJbgAEaNlkQbxaFGv_kn1AH6Ap6cSqgiESxR96_3QhVjNczYhGWrNp6ZuauaaO_btmc0oq7sLO2Fd0-ymq5zaML0ICd2C1rEp3DxjBRZzvwmrpRGzSxMbYN1FRrF1itvIAnnaTns0aNo-s4W3mGUmGAt54ALskjr4DEXD7P6r5JGvtOYsLVOZEO-1kJFQuNLqdqVARj2yBkNoGsN4JM2tXhTr7pcMBPOmb0Z7pkkajTBa-D50soacXwN1G9v1IohThVkojTJa0Ymmoyy3l9KPnDEe317ueAbzwCvTvz88OBzucHu7__xMew5XBeHicHR-Mjh7AVY5grwlyXIfVs_nCPUSwdpY_ak2CQXbBRvgTI6xUww |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4amzTxgrgvMMAgkHiJujmOEyNNaGOruo1VExpob5FjO6WIJaVpQfsB_Dj-Fec4SaHi8raHSlF9FDk-F3_HPheA504ZY1MZh1Zu6VDkLgrzRCnUeGmlVLGVPov_ZCgH78XReXy-Aj-6XBgKq-xsojfUtjJ0Rt6LqE4MTxBe9Io2LOJ0v_968iWkDlJ009q109BtmwW748uNtUkex-7yG7pz9c7hPvL-Bef9g7M3g7DtOBAaNBg8dLj5qaKIYyOV0Sam3AkKvxTCCRcZI9NUC-sQo_O40M5y6ax0gufCFgKRB772GqwluOmjsq3tHQxP3y0OfBBIxTLa7qobbfHeJ8qlpfpaS3uibx3wN7z7Z9jm73Da74f9m3CjBbJst5G8W7DiytuwftJe1d-B701uDLu4dJ-rsWUlharr-qJmI9wMCNyy0ZxqbFHc_Sv2Af2Bpr0TqwqGqBR_U1fT5VjN0LJRSWnNxqUfataaCBfvmkwpwbgLQWNfNZKXs_ounF0FB-7BalmVbgMYQUdc78Lq2InEqNQmSJvKKNEuNdt5AM-6Rc8mTWWPrKnhzDPiDAW_8QD2iB0LAirG7f-opqOs1e0sKVCwU-20iyMhc6HRBVVCRjyyBcJrG8Bmx8ystRB19kueA3i6GEbdpgsbjTyZexo6ZUKvL4D7De8XM4kUQi9FM0yXpGJpqssj5fijrx-OLrB3QwN46QXo35-fHQ12OT08-P8nPIF1VMbs7eHw-CFc54j7mnjHTVidTefuEeK2Wf641QgG2RXr4E_pDlj- |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Beyond+myeloid+neoplasms+germline+guidelines%3A+Validation+of+the+thresholds+criteria+in+the+search+of+germline+predisposition+variants&rft.jtitle=EJHaem&rft.au=Mestre%2C+Julia&rft.au=Chaparro%2C+Lorea&rft.au=Manzanares%2C+Ana&rft.au=Xicoy%2C+Blanca&rft.date=2024-10-01&rft.issn=2688-6146&rft.eissn=2688-6146&rft.volume=5&rft.issue=5&rft.spage=1021&rft.epage=1027&rft_id=info:doi/10.1002%2Fjha2.1012&rft.externalDBID=10.1002%252Fjha2.1012&rft.externalDocID=JHA21012 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2688-6146&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2688-6146&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2688-6146&client=summon |